Additionally, the 36-month beta value for SEEL is 1.89. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SEEL is 2.71M and currently, short sellers hold a 5.02% ratio of that float. The average trading volume of SEEL on July 23, 2024 was 496.12K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SEEL) stock’s latest price update
The stock price of Seelos Therapeutics Inc (NASDAQ: SEEL) has plunged by -6.58 when compared to previous closing price of 0.55, but the company has seen a -1.66% decline in its stock price over the last five trading sessions. investorplace.com reported 2024-07-08 that Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn’t a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy).
SEEL’s Market Performance
SEEL’s stock has fallen by -1.66% in the past week, with a monthly drop of -31.98% and a quarterly drop of -80.94%. The volatility ratio for the week is 8.89% while the volatility levels for the last 30 days are 15.31% for Seelos Therapeutics Inc The simple moving average for the past 20 days is -14.51% for SEEL’s stock, with a -95.98% simple moving average for the past 200 days.
Analysts’ Opinion of SEEL
Many brokerage firms have already submitted their reports for SEEL stocks, with ROTH Capital repeating the rating for SEEL by listing it as a “Buy.” The predicted price for SEEL in the upcoming period, according to ROTH Capital is $8 based on the research report published on September 27, 2021 of the previous year 2021.
Guggenheim, on the other hand, stated in their research note that they expect to see SEEL reach a price target of $8. The rating they have provided for SEEL stocks is “Buy” according to the report published on July 01st, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to SEEL, setting the target price at $10 in the report published on June 01st of the previous year.
SEEL Trading at -53.61% from the 50-Day Moving Average
After a stumble in the market that brought SEEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.87% of loss for the given period.
Volatility was left at 15.31%, however, over the last 30 days, the volatility rate increased by 8.89%, as shares sank -21.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -77.94% lower at present.
During the last 5 trading sessions, SEEL fell by -1.66%, which changed the moving average for the period of 200-days by -98.92% in comparison to the 20-day moving average, which settled at $0.5896. In addition, Seelos Therapeutics Inc saw -95.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SEEL starting from Mehra Raj, who purchase 75,757 shares at the price of $1.32 back on Dec 01 ’23. After this action, Mehra Raj now owns 185,142 shares of Seelos Therapeutics Inc, valued at $99,999 using the latest closing price.
Golembiewski Michael Joseph, the Chief Financial Officer of Seelos Therapeutics Inc, purchase 83,000 shares at $1.21 during a trade that took place back on Nov 30 ’23, which means that Golembiewski Michael Joseph is holding 86,450 shares at $100,222 based on the most recent closing price.
Stock Fundamentals for SEEL
Current profitability levels for the company are sitting at:
- -19.06 for the present operating margin
- 0.97 for the gross margin
The net margin for Seelos Therapeutics Inc stands at -13.74. The total capital return value is set at 1.14.
Based on Seelos Therapeutics Inc (SEEL), the company’s capital structure generated -0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -1.39. The debt to equity ratio resting at -0.4. The interest coverage ratio of the stock is -5374.57.
Currently, EBITDA for the company is -40.44 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 7.13. The receivables turnover for the company is 2.04for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.10.
Conclusion
In conclusion, Seelos Therapeutics Inc (SEEL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
